JO3256B1 - صياغات من مركبات عضوية - Google Patents

صياغات من مركبات عضوية

Info

Publication number
JO3256B1
JO3256B1 JOP/2014/0069A JOP20140069A JO3256B1 JO 3256 B1 JO3256 B1 JO 3256B1 JO P20140069 A JOP20140069 A JO P20140069A JO 3256 B1 JO3256 B1 JO 3256B1
Authority
JO
Jordan
Prior art keywords
formulations
organic compounds
pharmaceutically acceptable
relates
present
Prior art date
Application number
JOP/2014/0069A
Other languages
English (en)
Inventor
Kochhar Charu
Quinton Jacques
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3256B1 publication Critical patent/JO3256B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12136—Balloons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027—Type of occlusion
    • A61B17/1204—Type of occlusion temporary occlusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1002—Balloon catheters characterised by balloon shape
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205—Introduction devices
    • A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
    • A61B2017/12068—Details concerning the detachment of the occluding device from the introduction device detachable by heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205—Introduction devices
    • A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
    • A61B2017/12086—Details concerning the detachment of the occluding device from the introduction device magnetically detachable

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Medical Informatics (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Surgical Instruments (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبات صيدلانية صلبة تتضمن مثبط الفوسفاتيديل إنوسيتول 3-كيناز المركب 4-(ثلاثي فلورو ميثيل) -5-(6،2-ثنائي مورفولينو بيريميدنـ-4-ـيل) بيريدينـ-2-امين أو ملح منه مقبول صيدلانيا، فيومارات ستياريل صوديوم ، واختياريا ناقل واحد على الأقل مقبول صيدلانيا. يتعلق الاختراع الحالي أيضا بعمليات لتحضيرهم واستخدامهم كأدوية لعلاج السرطان.
JOP/2014/0069A 2013-03-06 2014-03-04 صياغات من مركبات عضوية JO3256B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361773492P 2013-03-06 2013-03-06

Publications (1)

Publication Number Publication Date
JO3256B1 true JO3256B1 (ar) 2018-09-16

Family

ID=50342366

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0069A JO3256B1 (ar) 2013-03-06 2014-03-04 صياغات من مركبات عضوية

Country Status (28)

Country Link
US (2) US9474534B2 (ar)
EP (1) EP2964200B1 (ar)
JP (1) JP6313343B2 (ar)
KR (1) KR102233757B1 (ar)
CN (1) CN105073099B (ar)
AR (2) AR095032A1 (ar)
AU (1) AU2014224238B2 (ar)
BR (1) BR112015021097B1 (ar)
CA (1) CA2904032C (ar)
CL (1) CL2015002466A1 (ar)
EA (1) EA028301B1 (ar)
ES (1) ES2634020T3 (ar)
IL (1) IL240579B (ar)
JO (1) JO3256B1 (ar)
MA (1) MA38358B1 (ar)
MX (1) MX370175B (ar)
MY (1) MY174648A (ar)
NZ (1) NZ711015A (ar)
PE (1) PE20151607A1 (ar)
PH (1) PH12015501945A1 (ar)
PL (1) PL2964200T3 (ar)
PT (1) PT2964200T (ar)
SG (1) SG11201506392VA (ar)
TN (1) TN2015000386A1 (ar)
TW (1) TW201442712A (ar)
UA (1) UA114948C2 (ar)
WO (1) WO2014136048A1 (ar)
ZA (1) ZA201505830B (ar)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498604B2 (en) 1997-11-12 2016-11-22 Genesis Technologies Llc Medical device and method
US10335577B2 (en) 2010-05-19 2019-07-02 Nfinium Vascular Technologies, Llc Augmented delivery catheter and method
US9561094B2 (en) 2010-07-23 2017-02-07 Nfinium Vascular Technologies, Llc Devices and methods for treating venous diseases
EP3151904A4 (en) 2014-06-04 2018-02-14 Nfinium Vascular Technologies, LLC Low radial force vascular device and method of occlusion
IL256299B2 (en) * 2015-06-30 2023-11-01 Genentech Inc Immediate-release tablets containing a drug and processes for creating the tablets
FI130702B1 (en) * 2018-12-18 2024-01-26 Miikka Frant Device suitable for insertion into the vein of a human patient
WO2020242795A1 (en) * 2019-05-24 2020-12-03 Eisai R&D Management Co., Ltd. A method for treating cancer with an oral dosage form of an estrogen receptor-alpha inhibitor
EP4199798A1 (en) * 2020-09-27 2023-06-28 Boston Scientific Scimed Inc. Expandable guide devices, systems, and methods
WO2022170187A1 (en) 2021-02-05 2022-08-11 Pyne Devaraj Detachable balloon embolization device and methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE206304T1 (de) * 1995-12-27 2001-10-15 Janssen Pharmaceutica Nv Bioadhesive feste arzneimittelform
US5916235A (en) 1997-08-13 1999-06-29 The Regents Of The University Of California Apparatus and method for the use of detachable coils in vascular aneurysms and body cavities
WO1999039649A1 (en) * 1998-02-10 1999-08-12 Dubrul William R Occlusion, anchoring, tensioning and flow direction apparatus and methods for use
US6066157A (en) 1998-09-16 2000-05-23 Medtronics Ave, Inc. Anchor joint for coaxial balloon dilatation catheter
US6368338B1 (en) 1999-03-05 2002-04-09 Board Of Regents, The University Of Texas Occlusion method and apparatus
US7331973B2 (en) 2002-09-30 2008-02-19 Avdanced Cardiovascular Systems, Inc. Guide wire with embolic filtering attachment
US7618435B2 (en) * 2003-03-04 2009-11-17 Nmt Medical, Inc. Magnetic attachment systems
JO2660B1 (ar) * 2006-01-20 2012-06-17 نوفارتيس ايه جي مثبطات الكاينيز Pi-3 وطرق استخدامها
KR20110050549A (ko) * 2008-09-03 2011-05-13 버텍스 파마슈티칼스 인코포레이티드 공-결정 및 이를 포함하는 제약 제제
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
IN2012DN03271A (ar) * 2009-10-23 2015-10-23 Merck Sharp & Dohme
US8992540B2 (en) 2010-07-22 2015-03-31 Kyphon Sarl Adjustable surgical instruments and methods of use and fabrication
WO2012060847A1 (en) * 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
EP3127492B1 (en) 2011-06-03 2023-01-18 Covidien LP Embolic implant
WO2014164535A1 (en) 2013-03-11 2014-10-09 Ferry Steven J A guidewire/ partial occluder for intraluminal travel

Also Published As

Publication number Publication date
CA2904032C (en) 2021-02-16
TN2015000386A1 (en) 2017-01-03
PL2964200T3 (pl) 2017-09-29
AU2014224238B2 (en) 2016-07-14
IL240579A0 (en) 2015-09-24
EP2964200B1 (en) 2017-04-19
US20160045202A1 (en) 2016-02-18
WO2014136048A1 (en) 2014-09-12
UA114948C2 (uk) 2017-08-28
BR112015021097B1 (pt) 2022-08-30
TW201442712A (zh) 2014-11-16
PH12015501945B1 (en) 2016-01-11
EP2964200A1 (en) 2016-01-13
BR112015021097A2 (pt) 2017-07-18
MA38358A1 (fr) 2016-11-30
US9474534B2 (en) 2016-10-25
CL2015002466A1 (es) 2016-03-04
CN105073099A (zh) 2015-11-18
MA38358B1 (fr) 2017-07-31
MY174648A (en) 2020-05-05
KR102233757B1 (ko) 2021-03-30
NZ711015A (en) 2020-02-28
AR095032A1 (es) 2015-09-16
AU2014224238A1 (en) 2015-09-03
CN105073099B (zh) 2018-10-26
AR128459A2 (es) 2024-05-08
HK1212244A1 (en) 2016-06-10
IL240579B (en) 2019-08-29
JP6313343B2 (ja) 2018-04-18
CA2904032A1 (en) 2014-09-12
ES2634020T3 (es) 2017-09-26
US20160015643A1 (en) 2016-01-21
PE20151607A1 (es) 2015-11-26
EA201591649A1 (ru) 2016-01-29
EA028301B1 (ru) 2017-10-31
KR20150123248A (ko) 2015-11-03
MX370175B (es) 2019-12-04
US10342547B2 (en) 2019-07-09
PT2964200T (pt) 2017-07-25
ZA201505830B (en) 2017-07-26
SG11201506392VA (en) 2015-09-29
JP2016510065A (ja) 2016-04-04
MX2015011705A (es) 2016-05-18
PH12015501945A1 (en) 2016-01-11

Similar Documents

Publication Publication Date Title
PH12015501945A1 (en) Formulations of organic compounds
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2013011086A (es) (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
PH12015502365A1 (en) Bace1 inhibitors
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
UA117154C2 (uk) Антагоністи s1p3
EA201692298A1 (ru) Производные карбоксамидов
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
TN2015000524A1 (en) Pharmaceutical compositions
MX2015012575A (es) Novedosos derivados de acrilamida como agentes contra la malaria.
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора